Announcement on Resolution of the Board of Directors
Filed with SSE · · 3 pages · Chinese
Earlier from InnoCare Pharma
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
- Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
- Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
- Announcement on the Cash Management Using Some Temporarily Idle Raised Funds and Deposit of Raised Funds through Call Deposits and Agreement Deposits
- InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
Later from InnoCare Pharma
- InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
- Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2023 STAR Market Restricted Stock Incentive Plan and Listing of Shares
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- InnoCare Releases 2025 Interim Results and Business Highlights
- Announcement on Grant of Reserved Restricted Shares to Grantees
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma